Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2

Status

Completed 3Terminated 1

Sponsor Class

NIH 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Lymphoid 4Genitourinary 4Gastrointestinal 4Other hematologic neoplasm 2Plasma cell 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 2Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × perifosine × Genitourinary × Clear all
NCT00448721 2018-03-01

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

AEterna Zentaris

Phase 2 Completed
24 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00498966 2018-02-05

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

AEterna Zentaris

Phase 2 Completed
50 enrolled
Genitourinary

Kidney Neoplasms

NCT00058214 2015-02-23

Perifosine in Treating Patients With Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

NCT00060437 2013-06-19

Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡